Terns Pharmaceuticals Inc (NASDAQ: TERN) has seen a rise in its stock price by 10.65% in relation to its previous close of $3.85. However, the company has experienced a 4.93% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-23 that Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024
Is It Worth Investing in Terns Pharmaceuticals Inc (NASDAQ: TERN) Right Now?
The 36-month beta value for TERN is also noteworthy at -0.12. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for TERN is 66.39M, and at present, short sellers hold a 8.95% of that float. The average trading volume of TERN on July 03, 2025 was 993.69K shares.
TERN’s Market Performance
TERN stock saw an increase of 4.93% in the past week, with a monthly gain of 29.88% and a quarterly increase of 66.41%. The volatility ratio for the week is 10.15%, and the volatility levels for the last 30 days are 8.62% for Terns Pharmaceuticals Inc (TERN). The simple moving average for the last 20 days is 10.02% for TERN stock, with a simple moving average of -14.17% for the last 200 days.
Analysts’ Opinion of TERN
Oppenheimer, on the other hand, stated in their research note that they expect to see TERN reach a price target of $82. The rating they have provided for TERN stocks is “Outperform” according to the report published on October 31st, 2024.
Mizuho gave a rating of “Buy” to TERN, setting the target price at $16 in the report published on June 22nd of the previous year.
TERN Trading at 25.62% from the 50-Day Moving Average
After a stumble in the market that brought TERN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.63% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TERN starting from Gengos Andrew, who purchase 10,000 shares at the price of $3.93 back on Jun 27 ’25. After this action, Gengos Andrew now owns 25,000 shares of Terns Pharmaceuticals Inc, valued at $39,283 using the latest closing price.
Burroughs Amy L., the Chief Executive Officer of Terns Pharmaceuticals Inc, purchase 23,314 shares at $3.87 during a trade that took place back on Jun 25 ’25, which means that Burroughs Amy L. is holding 47,083 shares at $90,230 based on the most recent closing price.
Stock Fundamentals for TERN
The total capital return value is set at -0.32. Equity return is now at value -32.12, with -30.84 for asset returns.
Based on Terns Pharmaceuticals Inc (TERN), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -58.02.
Currently, EBITDA for the company is -87.7 million with net debt to EBITDA at 1.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 30.89.
Conclusion
In summary, Terns Pharmaceuticals Inc (TERN) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
